SOLENO THERAPEUT. DL-001 (6XC) - Net Assets
Based on the latest financial reports, SOLENO THERAPEUT. DL-001 (6XC) has net assets worth €450.12 Million EUR (≈ $526.23 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€563.83 Million ≈ $659.18 Million USD) and total liabilities (€113.72 Million ≈ $132.94 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SOLENO THERAPEUT. DL-001 liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €450.12 Million |
| % of Total Assets | 79.83% |
| Annual Growth Rate | 124.27% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 603.53 |
SOLENO THERAPEUT. DL-001 - Net Assets Trend (2021–2025)
This chart illustrates how SOLENO THERAPEUT. DL-001's net assets have evolved over time, based on quarterly financial data. Also explore SOLENO THERAPEUT. DL-001 asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for SOLENO THERAPEUT. DL-001 (2021–2025)
The table below shows the annual net assets of SOLENO THERAPEUT. DL-001 from 2021 to 2025. For live valuation and market cap data, see 6XC stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €450.12 Million ≈ $526.23 Million |
+83.64% |
| 2024-12-31 | €245.11 Million ≈ $286.56 Million |
+55.62% |
| 2023-12-31 | €157.51 Million ≈ $184.14 Million |
+1422.10% |
| 2022-12-31 | €10.35 Million ≈ $12.10 Million |
-41.84% |
| 2021-12-31 | €17.79 Million ≈ $20.80 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SOLENO THERAPEUT. DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21801500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €881.49 Million | 195.84% |
| Total Equity | €450.12 Million | 100.00% |
SOLENO THERAPEUT. DL-001 Competitors by Market Cap
The table below lists competitors of SOLENO THERAPEUT. DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wenzhou Yihua Connector Co Ltd
SHE:002897
|
$2.31 Billion |
|
TAV HAVALIMAN.HLDG ADR/4
F:5THA
|
$2.31 Billion |
|
Enerflex Ltd.
TO:EFX
|
$2.31 Billion |
|
Pandox AB (publ)
ST:PNDX-B
|
$2.31 Billion |
|
Ningxia Jiaze Renewables Corp
SHG:601619
|
$2.31 Billion |
|
Jeju Semiconductor Corp
KQ:080220
|
$2.31 Billion |
|
Shenzhen Overseas Chinese Town Co Ltd
SHE:000069
|
$2.31 Billion |
|
Energisa S.A
SA:ENGI3
|
$2.30 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SOLENO THERAPEUT. DL-001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 245,113,000 to 450,115,000, a change of 205,002,000 (83.6%).
- Net income of 20,890,000 contributed positively to equity growth.
- Share repurchases of 100,146,000 reduced equity.
- New share issuances of 215,721,000 increased equity.
- Other factors increased equity by 68,537,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €20.89 Million | +4.64% |
| Share Repurchases | €100.15 Million | -22.25% |
| Share Issuances | €215.72 Million | +47.93% |
| Other Changes | €68.54 Million | +15.23% |
| Total Change | €- | 83.64% |
Book Value vs Market Value Analysis
This analysis compares SOLENO THERAPEUT. DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.42x to 5.21x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.34 | €44.86 | x |
| 2022-12-31 | €1.27 | €44.86 | x |
| 2023-12-31 | €4.97 | €44.86 | x |
| 2024-12-31 | €5.36 | €44.86 | x |
| 2025-12-31 | €8.61 | €44.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SOLENO THERAPEUT. DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.97%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.25x
- Recent ROE (4.64%) is above the historical average (-99.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -173.72% | 0.00% | 0.00x | 2.00x | €-32.69 Million |
| 2022 | -232.58% | 0.00% | 0.00x | 2.56x | €-25.10 Million |
| 2023 | -24.75% | 0.00% | 0.00x | 1.15x | €-54.74 Million |
| 2024 | -71.74% | 0.00% | 0.00x | 1.35x | €-200.36 Million |
| 2025 | 4.64% | 10.97% | 0.34x | 1.25x | €-24.12 Million |
Industry Comparison
This section compares SOLENO THERAPEUT. DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $353,958,690
- Average return on equity (ROE) among peers: -34.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SOLENO THERAPEUT. DL-001 (6XC) | €450.12 Million | -173.72% | 0.25x | $2.31 Billion |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $289.79 Million | -81.80% | 0.17x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $201.16 Million | -11.05% | 0.06x | $204.16 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.36 Billion | -38.77% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $796.12 Million | -42.03% | 0.30x | $1.82 Billion |
| BioNTech SE (22UA) | $267.00 Million | -17.98% | 1.45x | $20.05 Billion |
About SOLENO THERAPEUT. DL-001
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more